Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...
The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
Ashley is a former lead editor of mortgages and loans at Forbes Advisor. She graduated from Utah Tech University with a bachelor’s in English with an emphasis in creative writing. She began her career ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results